|Traded as||NASDAQ: BIVV
S&P 400 Component
(Spun off from Biogen)
|John G. Cox (CEO)
Number of employees
Bioverativ Inc. is an American multinational biotechnology, specializing in the discovery, development, and delivery of therapies for the treatment of haemophilia. Bioverativ competes with Baxalta, Pfizer and Novo Nordisk. The company trades on the NASDAQ exchange under the ticker symbol BIVV.
In May 2016 Biogen announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company. In August, the company announced that the spun off company would be called Bioverativ in order to show heritage with Biogen, and would be spun off in early 2017. On December 22, the Securities and Exchange Commission approved Bioverativ's registration statement, with the official separation date of the two companies being pegged at February 2017. In February, Biogen investors received a special dividend of one share of Bioverativ stock for every two shares of Biogen stock held as of January 17. Bioverativ began trading on January 12, 2017.
In May 2017, the company announced it would acquire True North Therapeutics for $825 million, strengthening Bioverativ's pipeline with the acquisition of TNT009 – a treatment for cold agglutinin disease.
The company has two current products; Alprolix and Eloctate, both products provided combined revenues of $604 million in 2015, and $640 million in the first nine months of 2016 (contributing to ~6% of Biogens' total revenue.
In BIVV 14 funds of 2184 total. Show all
|Fund name||Ticker shares|
|COLUMBIA WANGER ASSET MANAGEMENT LLC||1.03M|
|JANUS CAPITAL MANAGEMENT LLC||0.36M|
|Numeric Investors LLC||0.23M|
|EDGE ASSET MANAGEMENT, INC||0.16M|
|AHL Partners LLP||73634|
|ROCKEFELLER FINANCIAL SERVICES INC||37102|
|CAPSTONE ASSET MANAGEMENT CO||16201|
|Quotient Investors, LLC||7351|
|KCG Holdings, Inc.||6759|
|Geneva Advisors, LLC||6366|
|LBA Wealth Management, LLC||758|
|Weaver C. Barksdale & Associates, Inc.||113|
|GLG Partners LP||71|